HC Wainwright Brokers Decrease Earnings Estimates for SNDX

Key Points

• HC Wainwright lowered Syndax Pharmaceuticals’ Q3 2026 EPS estimate to a loss of $0.48 from $0.21, while maintaining its Buy rating and $38 price target.
• Syndax reported a quarterly loss of $0.55 per share, missing the $0.45 consensus estimate, and revenue of $72.79 million versus expectations of $79.36 million. Revenue still grew 91.8% year over year.
• Analyst sentiment remains broadly positive, with 12 Buy ratings and one Sell rating producing a Moderate Buy consensus and an average price target of $42.36.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Investment analysts at HC Wainwright cut their Q3 2026 earnings estimates for Syndax Pharmaceuticals in a report issued on Wednesday, August 5th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.48) per share for the quarter, down from their previous forecast of ($0.21). HC Wainwright currently has a "Buy" rating and a $38.00 price target on the stock. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals' Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at $0.84 EPS.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings downgraded Syndax Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, July 28th. UBS Group reissued a "buy" rating on shares of Syndax Pharmaceuticals in a research report on Friday, June 12th. Barclays raised their price target on shares of Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an "overweight" rating in a report on Friday, May 1st. Finally, Bank of America restated a "buy" rating on shares of Syndax Pharmaceuticals in a research report on Wednesday. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Syndax Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $42.36.

Syndax Pharmaceuticals Trading Down 0.8%

NASDAQ SNDX opened at $19.76 on Friday. The firm has a market capitalization of $1.75 billion, a PE ratio of -7.87 and a beta of 0.40. The business's 50-day moving average price is $20.41 and its two-hundred day moving average price is $21.37. The company has a current ratio of 6.77, a quick ratio of 5.06 and a debt-to-equity ratio of 38.95. Syndax Pharmaceuticals has a 12 month low of $12.10 and a 12 month high of $25.59.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The company had revenue of $72.79 million for the quarter, compared to the consensus estimate of $79.36 million. Syndax Pharmaceuticals had a negative return on equity of 372.94% and a negative net margin of 87.52%.The firm's revenue for the quarter was up 91.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.83) earnings per share.

Insider Activity

In related news, CEO Michael A. Metzger sold 32,375 shares of the firm's stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total transaction of $784,770.00. Following the completion of the sale, the chief executive officer owned 484,843 shares of the company's stock, valued at $11,752,594.32. This trade represents a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Nicholas A.J. Botwood sold 34,280 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $18.00, for a total value of $617,040.00. Following the completion of the sale, the chief marketing officer owned 60,885 shares of the company's stock, valued at approximately $1,095,930. The trade was a 36.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 105,914 shares of company stock valued at $2,120,789. Corporate insiders own 4.80% of the company's stock.

Institutional Trading of Syndax Pharmaceuticals

Several large investors have recently modified their holdings of SNDX. Smartleaf Asset Management LLC lifted its position in shares of Syndax Pharmaceuticals by 2,698.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company's stock valued at $55,000 after acquiring an additional 2,564 shares during the period. Larson Financial Group LLC grew its holdings in Syndax Pharmaceuticals by 192.2% in the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company's stock worth $45,000 after purchasing an additional 1,922 shares during the period. Quantbot Technologies LP bought a new stake in Syndax Pharmaceuticals in the third quarter valued at $53,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Syndax Pharmaceuticals by 26.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company's stock valued at $89,000 after purchasing an additional 893 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Syndax Pharmaceuticals during the second quarter valued at about $66,000.

Key Headlines Impacting Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Syndax and set a $38 price target, despite lowering its target from $40. The revised target still implies significant upside from recent trading levels. Benzinga analyst price target report
• Neutral Sentiment: Syndax granted inducement stock options covering up to 59,250 shares to five new employees. The awards support hiring and retention, but could modestly dilute existing shareholders as the options vest over four years. Syndax inducement grants announcement
• Negative Sentiment: HC Wainwright reduced its long-term EPS forecasts, cutting its FY2029 estimate to $2.28 from $2.59 and its FY2030 estimate to $3.16 from $3.52. Although the firm remains bullish, the revisions and lower price target suggest more cautious expectations for future profitability.
• Negative Sentiment: Syndax’s second-quarter performance added pressure: the company reported a loss of $0.55 per share versus the expected $0.45 loss, while revenue of $72.79 million came in below the $79.36 million consensus. Revenue nonetheless increased 91.8% year over year, indicating strong commercial growth despite the earnings miss. Syndax Q2 2026 earnings call transcript

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax's research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company's lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source